Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Mirdametinib by SpringWorks Therapeutics for Letterer-Siwe Disease (Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis): Likelihood of Approval
Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Phase II for Letterer-Siwe Disease (Multifocal and multisystemic (disseminated)...
Mirdametinib by SpringWorks Therapeutics for Neurofibromatoses Type I (Von Recklinghausen's Disease): Likelihood of Approval
Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Pre-Registration for Neurofibromatoses Type I (Von Recklinghausen's Disease). According...
Mirdametinib by SpringWorks Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Risk adjusted net present value: What is the current valuation of SpringWorks Therapeutics's Mirdametinib?
Mirdametinib is a small molecule commercialized by SpringWorks Therapeutics, with a leading Pre-Registration program in Neurofibromatoses Type I (Von Recklinghausen's...
Risk adjusted net present value: What is the current valuation of SpringWorks Therapeutics's Mirdametinib?
Mirdametinib is a small molecule commercialized by SpringWorks Therapeutics, with a leading Phase II program in Neurofibromatoses Type I (Von...
Mirdametinib by SpringWorks Therapeutics for Low-Grade Glioma: Likelihood of Approval
Mirdametinib is under clinical development by SpringWorks Therapeutics and currently in Phase II for Low-Grade Glioma. According to GlobalData, Phase...